Q3 2021 13F Holders as of 9/30/2021
-
Type / Class
-
Equity / Common Stock, par value $0.0001
-
Shares outstanding
-
53M
-
Number of holders
-
160
-
Total 13F shares, excl. options
-
31.1M
-
Shares change
-
-214K
-
Total reported value, excl. options
-
$2.61B
-
Value change
-
-$72.9M
-
Put/Call ratio
-
2.31
-
Number of buys
-
72
-
Number of sells
-
-99
-
Price
-
$83.94
Significant Holders of Cardlytics, Inc. - Common Stock, par value $0.0001 (CDLX) as of Q3 2021
220 filings reported holding CDLX - Cardlytics, Inc. - Common Stock, par value $0.0001 as of Q3 2021.
Cardlytics, Inc. - Common Stock, par value $0.0001 (CDLX) has 160 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 31.1M shares
of 53M outstanding shares and own 58.72% of the company stock.
Largest 10 shareholders include CAS Investment Partners, LLC (5.15M shares), WELLINGTON MANAGEMENT GROUP LLP (3.8M shares), VANGUARD GROUP INC (2.88M shares), BlackRock Inc. (2.47M shares), JPMORGAN CHASE & CO (1.84M shares), 683 Capital Management, LLC (1.47M shares), Alua Capital Management LP (1.24M shares), KPS Global Asset Management UK Ltd (1.18M shares), MORGAN STANLEY (935K shares), and BAILLIE GIFFORD & CO (746K shares).
This table shows the top 160 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.